ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a £3.5m pre- IPO funding round.
GLASGOW, Scotland--(BUSINESS WIRE)--ILC Therapeutics, a Scottish biotech company, has announced that its unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 (the virus which causes COVID-19) in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta 1a. COVID-19 tries to slow down the body’s innate Interferon response to viral infection and Alfacyte™ is designed to help accelerate this response and prevent disease progression.
ILC Therapeutics, a Scottish biotech company, has announced that its unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 (the virus which causes COVID-19) in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta 1a. COVID-19 tries to slow down the body’s innate Interferon response to viral infection and Alfacyte™ is designed to help accelerate this response and prevent disease progression.
UK-based biotechnology firm ILC Therapeutics has announced a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.